AVAIL-T trial

Chief investigator - Professor Simon Wagner, University of Leicester
Cancer type - Burkitt lymphoma
A phase IIa trial of avelumab, an anti-PDL1 antibody, in relapsed and refractory peripheral T-cell lymphoma
Award start date: 01 Jan 2017
Award duration: 3 years (36 months)

Peripheral T-cell lymphoma (PTCL) is an aggressive and difficult to treat non-Hodgkin’s lymphoma that has relatively poor outcomes. A proportion of people with PTCL fail to response to first line treatment, or relapse after receiving treatment. Currently there are no licensed drugs in Europe for this group of people.

PTCL cells exist in an environment containing supporting cells of various subtypes. It is believed that targeting both the lymphoma cells directly and the supporting cells will be effective routes to treatment. Avelumab is an antibody directed against a cell surface molecule called PD-L1. Avelumab removes cells which express the cell surface protein, PD-L1, which can be found either on lymphoma cells, or on the supporting cells. It is also likely to have other mechanisms of action. Avelumab has been used to treat other cancer types with some success, so researchers want to find out if this drug will be an effective addition to treatments for PTCL.

The aims of this trial are to:

  •          Determine the overall response to avelumab
  •          Determine whether patient response is related to levels and pattern of PD-L1 expression

Eligibility criteria to be confirmed.

This trial is in set up, and we hope to bring you more information soon.